caa a22 4500 477072577 CHVBK 20180405111430.0 cr unu---uuuuu 170330e19961101xx s 000 0 eng 10.1007/BF00050997 doi (NATIONALLICENCE)springer-10.1007/BF00050997 Captopril does not acutely modulate plasma endothelin-1 concentration in human congestive heart failure [Elektronische Daten] [O. Grenier, F. Pousset, R. Isnard, H. Kalotka, A. Carayon, G. Maistre, P. Lechat, C. Guerot, D. Thomas, M. Komajda] Summary: Congestive heart failure (CHF) is a syndrome characterized by increased levels of angiotensin II (Ang II) and endothelin-1 (ET-1). In vitro, Ang II stimulates ET-1 release. The purpose of this study was to assess the effect of a single dose of an angiotensin-converting enzyme inhibitor (ACEI) captopril versus placebo on plasma endothelin concentration in human congestive heart failure. Captopril (25 mg, given orally) was compared with placebo in a group of 20 patients with systolic dysfunction in a double-blind randomized study. Plasma irET concentration was significantly increased in CHF patients compared with normal subjects (5.59 pg/ml±0.35 vs. 3.58 pg/ml±0.99, p<0.0002). Despite the decrease in systolic blood pressure and the increase in plasma renin activity, suggesting a significant blockade of the renin-angiotensin system, no difference in plasma irET-1 was observed between captopril and placebo. Our results suggest that captopril does not acutely influence irET-1 plasma concentration in human CHF. These data do not support the hypothesis that the acute vasodilator effect of a single dose of 25 mg of captopril given orally involves modulation of the increased plasma concentration of endothelin observed in CHF. Kluwer Academic Publishers, 1996 endothelin nationallicence congestive heart failure nationallicence angiotensin converting enzyme inhibitor nationallicence Grenier O. Boucicaut Hospital, Paris, France aut Pousset F. Pitié-Salpétrière Hospital, Paris, France aut Isnard R. Pitié-Salpétrière Hospital, Paris, France aut Kalotka H. Pitié-Salpétrière Hospital, Paris, France aut Carayon A. Pitié-Salpétrière Hospital, Paris, France aut Maistre G. Pitié-Salpétrière Hospital, Paris, France aut Lechat P. Pitié-Salpétrière Hospital, Paris, France aut Guerot C. Boucicaut Hospital, Paris, France aut Thomas D. Pitié-Salpétrière Hospital, Paris, France aut Komajda M. Pitié-Salpétrière Hospital, Paris, France aut Cardiovascular Drugs and Therapy Kluwer Academic Publishers 10/5(1996-11-01), 561-565 0920-3206 10:5<561 1996 10 10557 https://doi.org/10.1007/BF00050997 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00050997 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Grenier O. Boucicaut Hospital, Paris, France aut NATIONALLICENCE 700 1- Pousset F. Pitié-Salpétrière Hospital, Paris, France aut NATIONALLICENCE 700 1- Isnard R. Pitié-Salpétrière Hospital, Paris, France aut NATIONALLICENCE 700 1- Kalotka H. Pitié-Salpétrière Hospital, Paris, France aut NATIONALLICENCE 700 1- Carayon A. Pitié-Salpétrière Hospital, Paris, France aut NATIONALLICENCE 700 1- Maistre G. Pitié-Salpétrière Hospital, Paris, France aut NATIONALLICENCE 700 1- Lechat P. Pitié-Salpétrière Hospital, Paris, France aut NATIONALLICENCE 700 1- Guerot C. Boucicaut Hospital, Paris, France aut NATIONALLICENCE 700 1- Thomas D. Pitié-Salpétrière Hospital, Paris, France aut NATIONALLICENCE 700 1- Komajda M. Pitié-Salpétrière Hospital, Paris, France aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Kluwer Academic Publishers 10/5(1996-11-01), 561-565 0920-3206 10:5<561 1996 10 10557 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer